Donors commit $4.3 billion in vaccine funding to achieve historic milestone for GAVI Alliance

14 June 2011

Major public and private donors achieved a milestone in global health by committing funding to immunize more than 250 million of the world's poorest children against life-threatening diseases by 2015 and prevent more than four million premature deaths at a conference organized in London, UK, yesterday by the Global Alliance for Vaccines and Immunization (GAVI).

Donors committed $4.3 billion at the first pledging conference held by the GAVI Alliance. This exceeds an initial target of $3.7 billion, enabling GAVI to reach more children faster than planned and to accelerate the introduction of new vaccines. A portion of the pledges are conditional upon GAVI raising additional funds from new donors in the future. These pledges bring GAVI's total available resources for the period 2011 to 2015 to $7.6 billion.

UK and Gates Foundation largest donors

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight



More Features in Pharmaceutical